Skip to main content
Donald Durden, MD, Pediatric Hematology & Oncology, San Diego, CA

DonaldLeeDurdenMDPhD

Pediatric Hematology & Oncology • San Diego, CA

Cancer Genetics/Cancer Risk Assessment

Professor Emeritus, Pediatrics, UCSD School of Medicine

Join to view full profile

Dr. Durden is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Durden's full profile

Already have an account?

  • Office

    3010 Childrens Way
    2west
    San Diego, CA 92123
    Phone+1 858-966-5811
    Fax+1 858-309-6301

Summary

  • Dr. Donald Durden is a pediatric hematologist/oncologist in La Jolla, CA and is affiliated with Rady Children's Hospital - San Diego. He received his medical degree from University of Miami Miller School of Medicine and has been in practice 32 years. He specializes in cancer genetics/cancer risk assessment and solid tumor/neuro-oncology experimental therapeutics and is experienced in asparaginase, pathologic neovascularization, phosphatidylinositol 3-kinases, phosphorylation, and signal transducing adaptor proteins. He is a physician scientist with over 25 years of continuous NIH RO1 grant funding involved heavily into in silico drug discovery and development around novel molecular targets which include kinase, immuno-oncologic and epigenetic targets from target discovery efforts ongoing in his laboratory over the past 20 years.

    • SF1126 for Patients With Relapsed or Refractory Neuroblastoma - Full Text View -

    SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the activ

Education & Training

  • University of Washington
    University of WashingtonFellowship, Pediatric Hematology/Oncology, 1988 - 1993
  • University of Washington
    University of WashingtonResidency, Pediatrics, 1987 - 1988
  • Tower Health/St. Christopher's Hospital for Children
    Tower Health/St. Christopher's Hospital for ChildrenResidency, Pediatrics, 1985 - 1987
  • University of Miami Leonard M. Miller School of Medicine
    University of Miami Leonard M. Miller School of MedicineClass of 1985
  • University of Miami School of Medicine
    University of Miami School of MedicinePhD, 1979 - 1983
  • University of South Florida
    University of South FloridaB.S., Microbiology and Zoology, 1971 - 1977

Certifications & Licensure

  • GA State Medical License
    GA State Medical License Current
  • NE State Medical License
    NE State Medical License 2018 - 2022
  • CA State Medical License
    CA State Medical License 2010 - 2019
  • American Board of Pediatrics Pediatric Hematology-Oncology
  • Pediatric Hematology-OncologyPediatric Hematology-Oncology

Awards, Honors, & Recognition

  • Editorial Board Molecular Cancer Research AACR, 2009
  • TME NIH Study Section NIH, 2002-2007
  • Cancer Working Group USWNR, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Dual Targeting of PI3Kdelta and BRD4 Sensitizes Acute Lymphoblastic Leukemia to Chemotherapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Potential New Anti-Cancer Drug Class Inhibits Multiple Molecular Targets
    Potential New Anti-Cancer Drug Class Inhibits Multiple Molecular TargetsFebruary 2nd, 2017
  • Potential New Drug Class Hits Multiple Cancer Cell Targets, Boosting Efficacy and Safety
    Potential New Drug Class Hits Multiple Cancer Cell Targets, Boosting Efficacy and SafetyFebruary 1st, 2017

Grant Support

  • Development of dual inhibitor of PI3K/BRD4 for cancer therapeuticsNIH NCI2017–2022
  • Role of PTEN and PI-3 kinase in medulloblastomagenesisNIH NCI2017–2022
  • Overcoming BTK inhibitor resistance in B-cell malignanciesNIH NCI2019–2020
  • Maximum MYC control using dual PI-3K/BRD4 inhibitorsNIH NCI2018–2020
  • Phase I trial of dual PI-3K/BRD4 inhibitor SF1126 in hepatocellular carcinomaFDA2016–2020
  • Vascular Targeted PAN PI-3 Kinase Inhibitor Prodrug, SF1126 For Glioma TherapyNational Cancer Institute2010–2012
  • Role Of SYK And RAC2 In Regulation Of Hif1alpha And Neovascularization.National Heart, Lung, And Blood Institute2009–2010
  • Role Of SYK And RAC2 In Regulation Of Hif1alpha And Neovascularization.National Heart, Lung, And Blood Institute2009
  • Vascular Targeted PAN PI-3 Kinase Inhibitor Prodrug, SF1126 For Glioma TherapyNational Cancer Institute2009
  • Vascular Targeted PAN Pi-3kinase Inhibitor Prodrug, SF1126 For Glioma Therapy.National Cancer Institute2008
  • Pten/Aktp53 Signaling Axis In Tumor Induced AngiogenesisNational Cancer Institute2004–2006
  • Pten/Aktp53 Signaling Axis In Tumor Induced AngiogenesisNational Cancer Institute2002–2003
  • RAC2 In Integrin Macrophage FunctionNational Heart, Lung, And Blood Institute2002
  • Vascular Endothelial Cell Integrins In AngiogenesisNational Cancer Institute2000–2002
  • Phase II Study For Treatment Of Pediatric Brain TumorsNational Cancer Institute1999
  • Phase II Study For Treatment Of Pediatric Brain TumorsNational Cancer Institute1997–1998

Industry Relationships

  • Founder, SignalRx Pharmaceuticals Inc.Founder drug discovery group combinatorial in silico drug discovery multiple targets kinase, epigenetic and immuno-oncologic in natureDisclosure: Shareholder in this private company2012 - Present

Dr. Donald Durden, Dr. Donald Durden, MD, Dr. D Durden, Dr. Donald Lee Durden